John Garcia: Chairman, Independent Non-Executive Director
Mr. Garcia was appointed to the Board of the Company in September 2007. With a 25 year career in the health products industry, Mr. Garcia has been instrumental in the development and growth of several medical products and services companies. Mr. Garcia served for more than 10 years as President of Sulzermedica’s $300 million pacemaker business before it was acquired by Guidant in 1998. Mr. Garcia also held sales and marketing management positions with FHP (a California HMO), Bio Science (a national reference lab) and Pharmaseal (a division of American Hospital Supply Corporation).
Klaas de Boer: Non-Executive Director
Mr. De Boer was appointed to the board of the Company in September 2008. He has been operating at the intersection of technology, innovation and entrepreneurship for the past 10 years. His career started with McKinsey & Company in Amsterdam in 1991. In 1997 he left consulting to join a client, Baan Investment (later Vanenburg Group) in 1997, to build the corporate venturing activity. This team invested in enterprise software companies in the US, Europe and Israel. The portfolio he built included WebEx, the current market leader in web conferencing. Following his time at Vanenburg, Mr. De Boer spent several years as an independent (angel) investor, advisor and interim manager in a range of entrepreneurial companies. In 2006 Mr. De Boer joined the Entrepreneurs Fund, which he restructured and repositioned following the spin out of the Good Energies team and portfolio. Mr. De Boer sits on the boards of several other life sciences and medical technology companies. Mr. De Boer has an MSc. in Applied Physics from Delft University of Technology and an MBA from Insead.
Andrew Clark: Senior Independent Non-Executive Director
Dr. Clark received his PhD in Neuroscience from St. Andrews University and was a post-doctoral research fellow in pharmacology at the University of Oxford. He worked in London as a biotech analyst at Baring Securities. In 1995 Andrew co-founded Reabourne, Ltd., an investment management business focused on small capitalisation technology and biotechnology companies where he acted as portfolio manager of Finsbury Life Sciences and Finsbury Universal Life, as well as co-managing Finsbury Technology Trust. He left Reabourne 2003 following the sale of the business and currently works as a consultant in the biotechnology field. He has held a number of non-executive directorships of life science and investment companies and is currently a director of Tepnel Life Sciences, Plc. He was appointed to the Board of the Company in September 2007.
David Kravitz:Executive Director CEO
Mr. Kravitz was a company founder who has led the group since its inception in 1998. He is co-inventor of several of the group's key proprietary technologies and patents and co-author of initial machine preservation related scientific review papers and presentations.
Steven Mayer: Independent Non-Executive Director
Dr. Mayer is a Doctor of Medicine and holder of a chemical engineering degree with a more than 20 year career in diagnostics, devices and pharmaceuticals. While at Abbott Laboratories, he held several positions including Director in Abbott Diagnostics Division and Pharmaceutical Products Division, and gained experience in many areas including basic R&D, manufacturing, strategic planning, economics and outcomes research. Dr. Mayer currently has advisory and scientific consultant roles at various medical companies and is a Non-Executive Director of HBM Partners (Cayman).
Eric Swenden: Independent Non-Executive Director
Mr. Swenden has had a long and successful career in finance and company management having held senior positions on a number of public company boards including Vandemoortele Food Group and General Bank (largest Belgian bank prior to its merger with Fortis).
